MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Nursing & Healthcare International Journal
ISSN: 2575-9981

The Role of Pharmacogenetic Testing in Clinical Practice: A Path toward more Effective, Personalized and Cost-effective Care

Janson PR*

Assistant Professor of Graduate Nursing, Hofstra University, USA

***Corresponding author:** Patricia R Janson, Assistant Professor of Graduate Nursing, Hofstra University, USA, Tel: 9172242214; Email: Patricia.R.Janson@hofstra.edu

Review Article

Volume 9 Issue 2

Received Date: November 24, 2025

Published Date: December 04, 2025

DOI: 10.23880/nhij-16000339

Abstract

Psychiatric medication prescribing has historically relied on a trial-and-error methodology, often resulting in suboptimal outcomes, prolonged patient suffering, and increased healthcare costs. . As providers, we have a responsibility to consider evidence-based tools to reduce the burden of depression. In response to these limitations, psychopharmacogenetic (PPGx) testing has emerged as a promising tool to guide personalized medication choices based on an individual's genetic profile. This article examines the clinical and economic benefits of incorporating PPGx testing into psychiatric practice, focusing on its benefits in improving patient outcomes, minimizing adverse drug reactions (ADRs), and decreasing costs. Key pharmacokinetic genes such as CYP2D6 and CYP2C19 have been shown to significantly influence the metabolism of commonly prescribed psychiatric medications, including SSRIs, TCAs, and antipsychotics. Guidelines from the U.S. Food and the Clinical Pharmacogenetics Implementation Consortium (CPIC) increasingly support genetic-informed prescribing. Recent studies and meta-analyses demonstrate that PPGx-guided treatment leads to higher remission rates, better tolerability, and lower health care costs. This article also explores implementation challenges, ethical considerations, and future directions in the field. Overall, the integration of PPGx testing represents a significant shift in psychiatric care, aligning with APA-recommended evidence-based practice and the national trend toward personalized-precision medicine. Providers are encouraged to adopt this approach to promote safer, more effective, and economically sustainable mental health care.

Keywords: Psycho-Pharmacogenetic Testing; Psychiatric Medication; Psychiatry

Abbreviations

PPGx: Psychopharmacogenetic; ADRs: Adverse Drug Reactions; CPIC: Clinical Pharmacogenetics Implementation Consortium; MDD: Major Depressive Disorder; SSRIs: Selective Serotonin Reuptake Inhibitors, TCAs: Tricyclic Antidepressants; DPWG: Dutch Pharmacogenetics Working Group; HAM-D17: Hamilton Depression Rating Scale.

Introduction

Psychopharmacogenetic Testing

Psychiatric pharmacotherapy is an important component in the treatment of mental health disorders, yet its effectiveness is often impaired by the variability in patient response to medications. Depression is one of the most

common mental health disorders affecting individuals in the United States [1]. Approximately 30–50% of patients with major depressive disorder (MDD) fail to respond to their first antidepressant trial, and up to 80% experience adverse effects that may hinder treatment adherence by Greden JF, et al. [2]. The traditional "one-size-fits-all or trial and error" approach to prescribing often requires multiple trials before achieving therapeutic efficacy, a process that can take weeks or months and imposes considerable psychological and financial burdens on patients. Psychopharmacogenetics (PPGx), a subset of pharmacogenomics, aims to optimize drug therapy by identifying genetic variants that influence drug metabolism, transport, and receptor activity. In psychiatry, where pharmacological interventions target complex neurobiological systems and often involve polypharmacy, the promise of PPGx is particularly compelling. Genes such as CYP2D6 and CYP2C19 affect the metabolism of a wide range of psychiatric drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and antipsychotics. Testing for these variants enables providers to choose medications based on genetics, predict treatment response, and reduce the risk of adverse effects. In recent years, the FDA and the Clinical Pharmacogenetics Implementation Consortium (CPIC) have increasingly recognized the value of pharmacogenetic testing. The FDA now includes pharmacogenetic information in the labeling of over 40 psychiatric medications of US FDA [3]. Evidence from randomized controlled trials demonstrates the effectiveness of psychopharmacogenetic testing in the treatment of mental health disorders by Brown L, et al. [4].

Background

The Science of Psychopharmacogenetics

Pharmacogenetics examines the role of inherited genetic differences in drug metabolism and response. In psychiatric practice, the focus has primarily been on genes affecting pharmacokinetics and pharmacodynamics. Key Pharmacokinetic Genes 1. CYP2D6: This gene encodes an enzyme responsible for metabolizing approximately 25% of all prescription drugs, including many antidepressants and antipsychotics. Individuals may be classified as poor, intermediate, extensive (normal), or ultra-rapid metabolizers based on CYP2D6 activity. Poor metabolizers may experience toxicity at standard doses, while ultra-rapid metabolizers may fail to achieve therapeutic levels. Guidelines and Testing Frameworks, the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) provide evidence-based recommendations for genotype-based prescribing by Gammal RS, et al. [5]. In the U.S., pharmacogenetic labeling by the FDA offers guidance on gene-drug interactions, which clinicians can use to adjust doses or select alternative medications of US FDA [3].

Rationale for Psychopharmacogenetic Testing in Psychiatry

Improving patient outcomes is one of the primary benefits of psychopharmacogenetic testing in its capacity to improve patients outcome from Forester BP, et al. [6]. By tailoring drug selection and dosing to a patient's genetic profile, providers can avoid ineffective treatments, adverse drug reactions, and reduce the time to symptom remission. This is especially critical in psychiatric illnesses, where delays in effective treatment increase the risk of functional impairment, exacerbation of co-morbid conditions, increased risk of cardiovascular events, and suicide [1]. A large randomized controlled trial, the GUIDED study, found that patients receiving PPGx-guided care had significantly higher response and remission rates compared to those receiving treatment as usual [2]. Remission was achieved in 21.5% of patients in the guided group versus 8.5% in the treatment-as-usual group [2]. Reduction in Adverse Drug Reactions (ADRs) PPGx testing identifies individuals at risk for dose-related side effects by highlighting poor or ultra-rapid metabolism. For instance, a poor metabolizer of nortriptyline may develop anticholinergic toxicity at standard doses, while an ultra-rapid metabolizer of fluoxetine may see little benefit. Preemptive identification allows clinicians to avoid these issues. Cost-Effectiveness PPGx testing has been shown to reduce long-term healthcare costs. A systematic review by Morris S, et al. [7] demonstrated that 71% of studies evaluated demonstrated that pharmacogenetic testing was cost-effective.

Evidence Base and Clinical Utility

Numerous trials have validated the utility of PPGx testing in optimizing antidepressant therapy. The GUIDED study and a meta-analysis by Brown L, et al. [4] demonstrate that patients receiving guided therapy have a significantly higher rates of remission. Patients who received guided treatment had a significant reduction in symptom severity, measured by the Hamilton Depression Rating Scale (HAM-D17). Treatment implemented using psycho- pharmacogenetic testing demonstrated a 43 % improvement over treatment as usual. Patients in the guided group experienced fewer adverse drug reactions which leads to greater patient satisfaction and medication compliance. However, clinical trial results differed depending on which specific test was used, the population studied and the outcome measure. This may limit the generalizability of results.

Implementation in Clinical Practice

Testing Procedures PPGx tests are typically conducted using buccal swabs. Results include genotype, metabolic phenotype, and recommendations. Interpretation and an

assessment of barriers require clinical judgment. Barriers may include cost, lack of provider training, and limited EHR integration. Solutions include CME programs, clinical protocols, and broader insurance coverage.

Future Directions and Ethical Considerations

As psychopharmacogenetic testing becomes more available and its clinical utility is demonstrated for the treatment of mental health disorders, the promise of significant technological, clinical, and scientific advancements offers further expansion of precision-individualized treatment. Future research trends will most likely include polygenic risk scores, multi-omic approaches, and AI integration to enhance precision-individualized prescribing of psychotropic medication by Dhieb D, et al. [8].

Ethical considerations are central to psycho-pharmacogenetic testing. For example, many psychiatric patients have fluctuating decision making capacity related to their symptoms and providers must assess a patient's capacity and understanding before proceeding [9]. Providers must also explain the purpose, benefits, and limitations of testing. Providers must ensure that patients and their families understand that PPGx informs care but does not define the course of treatment or treatments outcome from Bousman CA, et al. [10]. Ultimately, ethical considerations for utilizing PPGx is grounded in the principles of autonomy, beneficence, justice, and non-maleficence, promoting informed individualized care as well as social responsibility in prescribing psychiatric medications and care.

Conclusion

Psychopharmacogenetic (PPGx) testing represents an important advancement in the evolution of personalized psychiatry. Patients continue to grapple with high rates of treatment failure, adverse drug reactions, and lengthy trial-and-error prescribing. The integration of genetic data into clinical decision-making offers a clinical benefit which can improve patient outcomes, patient satisfaction and reduce health care costs. By aligning medication selection and dosing with a patient's unique genetic profile, providers can improve treatment efficacy, minimize avoidable side effects, and foster improved adherence and satisfaction. These improvements will not only enhance individual health outcomes but also support more efficient use of healthcare resources, reducing healthcare costs, emergency interventions, and lost productivity due to unresolved psychiatric symptoms.

Beyond clinical benefits, PPGx testing also aligns with broader movements in modern medicine toward data-driven, patient-centered care. It empowers patients by providing greater transparency and rationale behind treatment decisions, while enabling providers to practice with increased confidence and precision. As evidence grows and implementation barriers, such as cost, infrastructure, and clinician training will need to be addressed, the ethical imperative to adopt this technology becomes more apparent. Incorporating pharmacogenetic testing into psychiatric practice is no longer a theoretical aspiration but a practical and scientifically grounded strategy for improving mental healthcare in diverse populations.

In the coming years, the expansion of multi-omic technologies, artificial intelligence, and polygenic risk scores will further define the clinical relevance of genetic testing in psychiatry. As these tools become more accessible and equitable, individualized psychiatric care, not guided by generalized treatment algorithms but by each patient's biological makeup, will increasingly become a reality.

Psychopharmacogenetic testing represents a transformative step toward precision-individualized psychiatry. By aligning medication with genetics, providers can improve patient care, minimize adverse reactions, and reduce costs.

References

1. Barry MJ, Nicholson WK, Silverstein M, Chelmow D, Coker T, et al. (2023) Screening for Depression and Suicide Risk in Adults. JAMA 329(23): 2057.

2. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, et al. (2019) Impact of Pharmacogenomics on Clinical Outcomes in Major Depressive Disorder in the Guided Trial: A Large, Patient- and Rater-blinded, Randomized, Controlled Study. J Psychiatr Res 111: 59-67.

3. US Food and Drug Administration (2022) Table of Pharmacogenetic Associations.

4. Brown L, Vranjkovic O, Li J, Yu K, Habbab TAI, et al. (2020) The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis. Pharmacogenomics 21(8): 559-569.

5. Gammal RS, Dunnenberger HM, Caudle KE, Swen JJ (2019) Pharmacogenomics Education and Clinical Practice Guidelines. In Pharmacogenomics, pp: 395-414.

6. Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, et al. (2020) Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults with Depression. Am J Geriatr Psychiatry 28(9): 933-945.

7. Morris S, Alsaidi A, Verbyla A, Cruz A, Macfarlane C, et al. (2022) Cost Effectiveness of Pharmacogenetic Testing for

Drugs with Clinical Pharmacogenetics Implementation Consortium (cpic) Guidelines: A Systematic Review. Clin Pharmacol Ther 112(6): 1318-1328.

8. Dhieb D, Bastaki K (2025) Pharmaco-multiomics: A New Frontier in Precision Psychiatry. Int J Mol Sci 26(3): 1082.

9. Dalal PK (2020) Consent in Psychiatry-Concept, Application & Implications. Indian J Med Res 151(1): 6-9.

10. Bousman CA, Maruf AAI, Marques DF, Brown LC, Muller DJ (2023) The Emergence, Implementation, and Future Growth of Pharmacogenomics in Psychiatry: A Narrative Review. Psychological Medicine 53(16): 7983-7993.